Eli Lilly's Tirzepatide shows reductions in blood sugar levels and weight

Drug candidate Tirzepatide for treating type II diabetes has shown significant reductions in average long-term blood glucose levels, A1C, and body weight, according to new Eli Lilly data.

Photo: Mike Blake/REUTERS / X00030

New data from US pharmaceutical company Eli Lilly shows significant reduction in long-term blood sugar levels, A1C, and the body weights of patients when using the firm's drug candidate Tirzepatide's highest dose at 15 mg, according to an Eli Lilly press release on Wednesday.

The new data come from the firm's two phase III programs called Surpass-3 and Surpass-5. Eli Lilly is testing Tirzepatide as a treatment for type II diabetes, since it combines effects from the two hormones GLP-1 and GIP. For this reason, industry people predict this may be a competitor for Novo Nordisk's GLP-1 drugs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs